NFE2L2 and lung carcinoma: In this paper, the authors first demonstrated that in lung cancer, the inactivation of Nrf2 leads to the inhibition of tumor growth, while the gain of function of this transcription factor favors the cancer cells’ metabolic reprogramming associated with tumor progression (viz., increasing the pentose phosphate pathway (PPP) and the tricarboxylic acid (TCA) cycle).